Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
